199679-02-2

Basic information

• Product Name: (E)-3-(4-(pyrrolidin-1-yl)phenyl)acrylic acid
• Synonyms: (E)-3-(4-(pyrrolidin-1-yl)phenyl)acrylic acid
• CAS NO: 199679-02-2
• Molecular Formula: C₁₃H₁₅NO₂
• Molecular Weight: 217.2637
• Mol File: 199679-02-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (E)-3-(4-(pyrrolidin-1-yl)phenyl)acrylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-3-(4-(pyrrolidin-1-yl)phenyl)acrylic acid(199679-02-2)
• EPA Substance Registry System: (E)-3-(4-(pyrrolidin-1-yl)phenyl)acrylic acid(199679-02-2)

Safety Data

• Hazardous Substances Data: 199679-02-2(Hazardous Substances Data)

Usage

General Description

(E)-3-(4-(pyrrolidin-1-yl)phenyl)acrylic acid is a chemical compound with the molecular formula C15H17NO2. It is an acrylic acid derivative that contains a pyrrolidinyl group. (E)-3-(4-(pyrrolidin-1-yl)phenyl)acrylic acid is commonly used in the field of pharmaceuticals and medicinal chemistry as a building block for synthesizing various drugs and bioactive molecules. It possesses specific structural features that make it useful for designing new compounds with potential biological activities. Additionally, it may also have applications in materials science and organic synthesis due to its reactivity and structural properties.

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 51980-54-2 4-(pyrrolidin-1-yl)benzaldehyde 
• 141-82-2 malonic acid 

Downstream Products

• 1374855-87-4 (E)-N-(2-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(pyrrolidin-1-yl)phenyl)acrylamide 

Relevant articles and documents

Identification and optimization of piperine analogues as neuroprotective agents for the treatment of Parkinson's disease via the activation of Nrf2/keap1 pathway

Parkinson's disease (PD) is a slowly progressive and complex neurodegenerative disorder. Up to date, there are no approved drugs that could slow or reverse the neurodegenerative process of PD. Here, we reported the synthesis of series of piperine analogues and the evaluation of their neuroprotective effects against hydrogen peroxide (H2O2) induced damage in the neuron-like PC12 cells. Among these analogues, 3b exhibited the most potent protection effect and its underlying mechanism was further investigated. Further results indicated that the ROS scavenging and cytoprotection effect of 3b might be related to the Nrf2 activation and upregulation of related phase II antioxidant enzymes, such as HO-1 and NQO1. In in vivo study, oral administration (100 mg/kg) of 3b significantly attenuated PD-associated behavioral deficits in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD and protected tyrosine hydroxylase-immunopositive dopaminergic neurons. Our results provided evidence that 3b might be a promising candidate for Parkinson's disease treatment.

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: Part 2

Melanin concentrating hormone receptor 1 (MCHR1) antagonists have potential for the treatment of obesity and several CNS disorders. In the preceding article, we have described a novel series of quinazolines as MCHR1 antagonists and demonstrated in vivo proof of principle with an early lead. Herein we describe the detailed SAR and SPR studies to identify an optimized lead candidate having good efficacy in a sub-chronic DIO model with a good cardiovascular safety window.